Our results showed that PG2 alone or in combination with GM-CSF+IL4 also enhanced the production of functional mDCs in the breast, colon, ovarian, liver, gastric, and brain cancers (Figure 6F and Supplementary Figure S1). Here, CSF2 is linked to brain cancer.